Literature DB >> 15729576

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp.

S V M Hordern1, J E Wright, A M Umpleby, F Shojaee-Moradie, J Amiss, D L Russell-Jones.   

Abstract

AIMS/HYPOTHESIS: The association of insulin detemir with non-esterified fatty acid binding sites on albumin may limit its transfer from the circulation into the extravascular extracellular space in adipose tissue and muscle, due to the capillary endothelial cell barrier. In the liver, the open sinusoids may expose hepatocytes to insulin detemir, enabling it to have a greater effect in the liver than in peripheral tissues.
METHODS: We investigated the effects of equipotent doses of insulin detemir and NPH insulin on hepatic glucose rate of appearance (Ra), peripheral glucose rate of disposal (Rd) and glycerol Ra (a measure of lipolysis) using stable isotope techniques. We also investigated the effects of these insulins on NEFA concentrations in seven healthy volunteers during a 16-h euglycaemic clamp. A higher dose of insulin detemir was also studied.
RESULTS: There was no difference in the glucose infusion profile between insulin detemir and NPH. Insulin detemir had a greater effect on mean suppression of glucose Ra (mean difference 0.24 mg kg(-1) min(-1); CI 0.09-0.39; p<0.01), and minimum glucose Ra, with minimum low dose detemir -0.10+/-0.15 mg.kg(-1).min(-1) and minimum NPH 0.17+/-0.10 mg.kg(-1).min(-1) (p<0.02). However, it had a lesser effect on mean suppression of NEFA concentrations (mean difference -0.10 mmol/l; CI -0.03 to -0.17; ANOVA, p<0.02) than NPH. The effect of insulin detemir on glucose Rd and glycerol Ra was not different from NPH. Following high-dose detemir, total glucose infused and maximum glucose Rd were higher (p<0.02, p<0.03) and plasma NEFA concentrations lower (p<0.01) than with low-dose determir. CONCLUSIONS/
INTERPRETATION: This study suggests that insulin detemir, when compared to NPH insulin, has a greater effect on the liver than on peripheral tissues and thus has the potential to restore the physiological insulin gradient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729576     DOI: 10.1007/s00125-005-1670-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  24 in total

1.  Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

Authors:  G A Brunner; G Sendhofer; A Wutte; M Ellmerer; B Søgaard; A Siebenhofer; S Hirschberger; G J Krejs; T R Pieber
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

Review 2.  Insulin: understanding its action in health and disease.

Authors:  P Sonksen; J Sonksen
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

3.  The Role of the Sinusoidal Endothelium in Liver Function.

Authors:  Jürg Reichen
Journal:  News Physiol Sci       Date:  1999-06

4.  Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans.

Authors:  F Shojaee-Moradie; J K Powrie; E Sundermann; M W Spring; A Schüttler; P H Sönksen; D Brandenburg; R H Jones
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

Review 5.  Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy.

Authors:  J A Janssen; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

6.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method.

Authors:  R STEELE; J S WALL; R C DE BODO; N ALTSZULER
Journal:  Am J Physiol       Date:  1956-09

Review 7.  Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future?

Authors:  P H Sönksen; D Russell-Jones; R H Jones
Journal:  Horm Res       Date:  1993

8.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients.

Authors:  M I Wurzburger; G M Prelevic; P H Sönksen; M Wheeler; L Balint-Peric
Journal:  Acta Diabetol       Date:  1995-06       Impact factor: 4.280

Review 10.  Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.

Authors:  P Hildebrandt
Journal:  Dan Med Bull       Date:  1991-08
View more
  26 in total

1.  Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients.

Authors:  K V Hendriksen; T Jensen; P Oturai; B Feldt-Rasmussen
Journal:  Diabetologia       Date:  2011-10-16       Impact factor: 10.122

Review 2.  Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.

Authors:  Israel Hartman
Journal:  Clin Med Res       Date:  2008-09-18

Review 3.  Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.

Authors:  Juntang Shao; Jennica L Zaro; Wei-Chiang Shen
Journal:  Tissue Barriers       Date:  2016-03-04

4.  Tissue selectivity of insulin detemir action in vivo.

Authors:  A M Hennige; T Sartorius; O Tschritter; H Preissl; A Fritsche; P Ruth; H-U Häring
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

5.  Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system.

Authors:  M C Moore; M S Smith; M K Turney; S Boysen; P E Williams
Journal:  Diabetes Obes Metab       Date:  2011-09       Impact factor: 6.577

6.  Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

Authors:  Katarina Raslová; Soren Can Tamer; Per Clauson; Diane Karl
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 7.  Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus.

Authors:  Harriet L Miles; Carlo L Acerini
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.

Authors:  F Smeeton; F Shojaee Moradie; R H Jones; L Westergaard; H Haahr; A M Umpleby; D L Russell-Jones
Journal:  Diabetologia       Date:  2009-08-26       Impact factor: 10.122

Review 9.  Defining the role of insulin detemir in Basal insulin therapy.

Authors:  Javier Morales
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Authors:  Kjeld Hermansen; Lene S Mortensen
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.